ES2187798T3 - Procedimiento de conservacion de virus recombinantes infecciosos, suspension acuosa viral y su utilizacion como medicamento. - Google Patents
Procedimiento de conservacion de virus recombinantes infecciosos, suspension acuosa viral y su utilizacion como medicamento.Info
- Publication number
- ES2187798T3 ES2187798T3 ES97933740T ES97933740T ES2187798T3 ES 2187798 T3 ES2187798 T3 ES 2187798T3 ES 97933740 T ES97933740 T ES 97933740T ES 97933740 T ES97933740 T ES 97933740T ES 2187798 T3 ES2187798 T3 ES 2187798T3
- Authority
- ES
- Spain
- Prior art keywords
- viral
- conservation
- procedure
- recombinant viruses
- medicinal product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000700605 Viruses Species 0.000 title abstract 4
- 208000015181 infectious disease Diseases 0.000 title abstract 3
- 230000002458 infectious effect Effects 0.000 title abstract 3
- 239000000725 suspension Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 230000003612 virological effect Effects 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9608851A FR2751343B1 (fr) | 1996-07-16 | 1996-07-16 | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2187798T3 true ES2187798T3 (es) | 2003-06-16 |
Family
ID=9494078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES97933740T Expired - Lifetime ES2187798T3 (es) | 1996-07-16 | 1997-07-15 | Procedimiento de conservacion de virus recombinantes infecciosos, suspension acuosa viral y su utilizacion como medicamento. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6451256B1 (OSRAM) |
| EP (1) | EP0853660B1 (OSRAM) |
| JP (1) | JP3681401B2 (OSRAM) |
| AT (1) | ATE231549T1 (OSRAM) |
| AU (1) | AU711409B2 (OSRAM) |
| CA (1) | CA2232604C (OSRAM) |
| DE (1) | DE69718612T2 (OSRAM) |
| DK (1) | DK0853660T3 (OSRAM) |
| ES (1) | ES2187798T3 (OSRAM) |
| FR (1) | FR2751343B1 (OSRAM) |
| WO (1) | WO1998002522A1 (OSRAM) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6544769B1 (en) * | 1996-12-13 | 2003-04-08 | Schering Corporation | Compostions comprising viruses and methods for concentrating virus preparations |
| US20080261289A1 (en) * | 1996-12-13 | 2008-10-23 | Schering-Plough Corporation | Compositions comprising viruses and methods for concentrating virus preparations |
| JP2002531418A (ja) * | 1998-12-03 | 2002-09-24 | アビジェン， インコーポレイテッド | アデノ随伴ウイルスの薬学処方物における使用のための賦形剤、およびそれにより構成される薬学処方物 |
| US6759050B1 (en) | 1998-12-03 | 2004-07-06 | Avigen, Inc. | Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith |
| US6225289B1 (en) * | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
| CA2364562A1 (fr) * | 1999-04-09 | 2000-10-19 | Aventis Pharma S.A. | Composition destinee a la conservation d'adenovirus recombinants infectieux |
| FR2791999B1 (fr) * | 1999-04-09 | 2001-09-07 | Aventis Pharma Sa | Composition destinee a la conservation d'adenovirus recombinants infectieux |
| US7456009B2 (en) | 2000-03-07 | 2008-11-25 | Merck & Co., Inc. | Adenovirus formulations |
| CA2399321C (en) * | 2000-03-07 | 2013-04-30 | Robert K. Evans | Adenovirus formulations |
| US20040101964A1 (en) * | 2000-05-10 | 2004-05-27 | Shigemitsu Takashima | Method of preparing virus vector |
| JP4550421B2 (ja) | 2001-12-12 | 2010-09-22 | メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド | ウイルスの保存のための組成物 |
| US20030232018A1 (en) * | 2002-01-18 | 2003-12-18 | Berlex Biosciences | Stabilized formulations of adenovirus |
| KR100507794B1 (ko) * | 2003-02-11 | 2005-08-17 | 한미약품 주식회사 | 고농도 레트로 바이러스 현탁액 제조 방법 |
| US20070148765A1 (en) * | 2003-11-19 | 2007-06-28 | Evans Robert K | Preservative-containing virus formulations |
| CN1922308A (zh) * | 2004-02-23 | 2007-02-28 | 克鲁塞尔荷兰公司 | 病毒纯化方法 |
| GB0502661D0 (en) * | 2005-02-09 | 2005-03-16 | Stabilitech Ltd | A desiccated product |
| ES2317517T5 (es) * | 2005-04-11 | 2016-01-21 | Crucell Holland B.V. | Purificación de virus usando ultrafiltración |
| CN1961961B (zh) * | 2005-11-11 | 2010-05-26 | 深圳市源兴生物医药科技有限公司 | 一种药物制剂及其制备方法 |
| NZ593235A (en) | 2008-11-03 | 2013-02-22 | Crucell Holland Bv | Method for the production of recombinant adenovirus serotype 35 |
| EA023816B1 (ru) | 2010-02-15 | 2016-07-29 | Круселл Холланд Б.В. | СПОСОБ ПРОДУЦИРОВАНИЯ ВИРУСНЫХ ЧАСТИЦ Ad26 |
| CN103118702A (zh) | 2010-09-20 | 2013-05-22 | 克鲁塞尔荷兰公司 | 活动性结核病的治疗性接种 |
| BR112013004582A2 (pt) | 2010-09-27 | 2016-09-06 | Crucell Holland Bv | método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária |
| EA201390810A1 (ru) | 2010-12-02 | 2013-09-30 | Онколитикс Байотек Инк. | Жидкие вирусные составы |
| WO2012075376A2 (en) | 2010-12-02 | 2012-06-07 | Oncolytics Biotech Inc. | Lyophilized viral formulations |
| PL2825640T3 (pl) | 2012-03-12 | 2016-10-31 | Partie rekombinowanych adenowirusów o zmienionych końcach | |
| US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| US9125870B2 (en) | 2012-03-22 | 2015-09-08 | Crucell Holland B.V. | Vaccine against RSV |
| AP2014007993A0 (en) | 2012-03-22 | 2014-10-31 | Crucell Holland Bv | Vaccine against RSV |
| WO2014009433A1 (en) | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterium resuscitation promoting factor for use as adjuvant |
| KR20150058152A (ko) | 2012-07-10 | 2015-05-28 | 트랜스진 에스아이 | 마이코박테리아 항원 백신 |
| US10899800B2 (en) | 2013-04-25 | 2021-01-26 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
| EP3010931B1 (en) | 2013-06-17 | 2018-06-13 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
| MX2016009072A (es) | 2014-01-09 | 2017-05-08 | Transgene Sa | Fusion de antigenos micobacterianos heterooligomericos. |
| US9721484B2 (en) | 2014-06-23 | 2017-08-01 | Humanetics Innovative Solutions, Inc. | Shoulder kit assembly for crash test dummy |
| CN120555373A (zh) | 2014-07-16 | 2025-08-29 | 特兰斯吉恩股份有限公司 | 用于表达免疫检查点调节因子的溶瘤病毒 |
| US10008130B2 (en) | 2014-09-17 | 2018-06-26 | Humanetics Innovative Solutions, Inc. | Omni-directional shoulder assembly for crash test dummy |
| CN107949397A (zh) | 2015-02-13 | 2018-04-20 | 特兰斯吉恩股份有限公司 | 免疫治疗疫苗和抗体组合治疗 |
| WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
| PL3283634T3 (pl) | 2015-04-14 | 2019-10-31 | Janssen Vaccines & Prevention Bv | Rekombinowany adenowirus eksprymujący dwa transgeny z dwukierunkowym promotorem |
| KR20180026734A (ko) | 2015-07-07 | 2018-03-13 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 가용성 융합-전 rsv f 폴리펩티드 |
| KR102638978B1 (ko) | 2015-07-07 | 2024-02-22 | 얀센 백신스 앤드 프리벤션 비.브이. | Rsv에 대한 백신 |
| KR20220041966A (ko) | 2016-04-05 | 2022-04-01 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 용해성 융합-전 rsv f 단백질 |
| EA201892250A1 (ru) | 2016-04-05 | 2019-03-29 | Янссен Вэксинс Энд Превеншн Б.В. | Вакцина против rsv |
| WO2017194655A1 (en) | 2016-05-12 | 2017-11-16 | Janssen Vaccines & Prevention B.V. | Potent and balanced bidirectional promoter |
| WO2017207480A1 (en) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
| ES2821876T3 (es) | 2016-06-20 | 2021-04-28 | Janssen Vaccines & Prevention Bv | Promotor bidireccional potente y equilibrado |
| JP7229151B2 (ja) | 2016-07-14 | 2023-02-27 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Ｈｐｖワクチン |
| TW201825674A (zh) | 2016-09-09 | 2018-07-16 | 美商艾斯合顧問有限公司 | 表現雙特異性接合分子的溶瘤病毒 |
| WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
| JP7110203B2 (ja) | 2016-12-28 | 2022-08-01 | トランジェーヌ | 腫瘍溶解性ウイルスおよび治療用分子 |
| JP6721797B2 (ja) | 2017-02-09 | 2020-07-15 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | 異種遺伝子発現のための強力で短いプロモーター |
| WO2018210871A1 (en) | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
| JP2020519663A (ja) | 2017-05-17 | 2020-07-02 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | Ｒｓｖ感染に対する防御免疫を誘導するための方法及び組成物 |
| WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
| MX2020002876A (es) | 2017-09-15 | 2020-07-22 | Janssen Vaccines & Prevention Bv | Metodo para la induccion segura de inmunidad contra el vsr. |
| WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
| JP7557738B2 (ja) | 2018-10-30 | 2024-09-30 | 国立大学法人 東京大学 | がん治療のための腫瘍溶解性ウイルス |
| JP2022513025A (ja) | 2018-11-13 | 2022-02-07 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 安定化された融合前ｒｓｖ ｆタンパク質 |
| US20230075527A1 (en) | 2020-01-31 | 2023-03-09 | Janssen Pharmaceuticals, Inc | Compositions and Methods for Preventing and Treating Coronavirus Infection - Sars-Cov-2 Vaccines |
| CN115484985A (zh) | 2020-03-19 | 2022-12-16 | 崔泽尔有限公司 | 温度响应病毒储存系统 |
| JP2023533584A (ja) | 2020-07-13 | 2023-08-03 | トランジェーヌ | 免疫低下の処置 |
| WO2022161502A1 (zh) | 2021-02-01 | 2022-08-04 | 羿尊生物医药（浙江）有限公司 | 一种靶向蛋白降解系统及其应用 |
| MX2023009738A (es) | 2021-02-19 | 2023-08-30 | Janssen Vaccines & Prevention Bv | Antigenos de rsv fb prefusion estabilizados. |
| WO2023020939A1 (en) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023025899A2 (en) | 2021-08-26 | 2023-03-02 | Transgene | Delivery system for targeting genes of the interferon pathway |
| WO2023111725A1 (en) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
| WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| CN119654339A (zh) | 2022-07-01 | 2025-03-18 | 特兰斯吉恩股份有限公司 | 包含表面活性蛋白-d和tnfsf成员的融合蛋白 |
| TW202413636A (zh) | 2022-08-18 | 2024-04-01 | 法商傳斯堅公司 | 嵌合痘病毒 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2668064B1 (fr) * | 1990-10-23 | 1994-12-16 | Transgene Sa | Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne. |
| US5658779A (en) * | 1992-03-20 | 1997-08-19 | Ligochem, Inc. | Method of adsorbing viruses from fluid compositions |
| EP0728195A1 (en) * | 1993-10-12 | 1996-08-28 | Chiron Corporation | Methods for preserving recombinant viruses |
| FR2711523B1 (fr) * | 1993-10-26 | 1996-02-16 | Transgene Sa | Procédé de préparation d'un aérosol viral. |
| US5545555A (en) * | 1994-07-25 | 1996-08-13 | Microtest, Inc. | Microbial transport media |
| US5559099A (en) * | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
| US5616487A (en) * | 1994-09-15 | 1997-04-01 | Aastrom Biosciences, Inc. | Stabilized retrovirus compositions |
| US5932223A (en) * | 1996-09-26 | 1999-08-03 | Merck & Co., Inc. | Rotavirus vaccine formulations |
-
1996
- 1996-07-16 FR FR9608851A patent/FR2751343B1/fr not_active Expired - Fee Related
-
1997
- 1997-07-15 CA CA002232604A patent/CA2232604C/fr not_active Expired - Lifetime
- 1997-07-15 AT AT97933740T patent/ATE231549T1/de active
- 1997-07-15 US US09/043,187 patent/US6451256B1/en not_active Expired - Lifetime
- 1997-07-15 ES ES97933740T patent/ES2187798T3/es not_active Expired - Lifetime
- 1997-07-15 AU AU36986/97A patent/AU711409B2/en not_active Expired
- 1997-07-15 WO PCT/FR1997/001308 patent/WO1998002522A1/fr not_active Ceased
- 1997-07-15 EP EP97933740A patent/EP0853660B1/fr not_active Expired - Lifetime
- 1997-07-15 JP JP50569198A patent/JP3681401B2/ja not_active Expired - Lifetime
- 1997-07-15 DE DE69718612T patent/DE69718612T2/de not_active Expired - Lifetime
- 1997-07-15 DK DK97933740T patent/DK0853660T3/da active
-
2002
- 2002-08-15 US US10/218,564 patent/US20030082206A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998002522A1 (fr) | 1998-01-22 |
| DK0853660T3 (da) | 2003-05-05 |
| ATE231549T1 (de) | 2003-02-15 |
| JP3681401B2 (ja) | 2005-08-10 |
| FR2751343A1 (fr) | 1998-01-23 |
| AU711409B2 (en) | 1999-10-14 |
| EP0853660A1 (fr) | 1998-07-22 |
| JP2000500026A (ja) | 2000-01-11 |
| US20030082206A1 (en) | 2003-05-01 |
| AU3698697A (en) | 1998-02-09 |
| US6451256B1 (en) | 2002-09-17 |
| DE69718612D1 (de) | 2003-02-27 |
| DE69718612T2 (de) | 2003-11-06 |
| EP0853660B1 (fr) | 2003-01-22 |
| CA2232604A1 (fr) | 1998-01-22 |
| CA2232604C (fr) | 2005-06-28 |
| FR2751343B1 (fr) | 1998-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2187798T3 (es) | Procedimiento de conservacion de virus recombinantes infecciosos, suspension acuosa viral y su utilizacion como medicamento. | |
| DE60239394D1 (de) | Onkolytische virustherapie | |
| KR20030025907A (ko) | 카세인 유도 펩타이드 및 이들의 치료 용도 | |
| UA66744C2 (en) | 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections | |
| SG17493G (en) | Ozone decontamination of blood and blood products | |
| CY1106152T1 (el) | Νεα ανοσογονα αντι-hiv (ανατοξινες), μεθοδοι παρασκευης και εφαρμογη στην προληψη και στην αγωγη του aids | |
| ES2114073T3 (es) | Regeneracion del higado inducida por morfogenes. | |
| FI961536A0 (fi) | Menetelmä virusten inaktivoimiseksi polyalkeeniglykolin läsnäollessa samoin kuin siten saatu farmaseuttinen valmiste | |
| DE60009146D1 (de) | Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und ein herzglykosid enthalten | |
| DE69914911D1 (de) | Pharmazeutische präparate zur bekämpfung oder prophylaxe von mikroorganismen infizierten oberflächen | |
| EA199800526A1 (ru) | Производные бензимидазола и их применение для лечения вирусных инфекций | |
| KR20040078639A (ko) | 카세인 유도 펩타이드 및 이들의 치료 용도 | |
| AU2251302A (en) | Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2 | |
| ES2062990T3 (es) | Vacunas, que contienen la proteina f del virus del sida. | |
| BG100835A (bg) | Ново лекарствено средство за лечение на вирусни инфекции на дихателните пътища | |
| ATE306275T1 (de) | Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und lithium enthalten | |
| DE60040910D1 (de) | Inaktivierte zytokine zur immunisierung | |
| ATE497784T1 (de) | Arznei zur prävention und behandlung von herzerkrankungen mit cd9-gen | |
| DE69803052D1 (de) | Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt | |
| RU98117264A (ru) | Способ инактивации вируса иммунодефицита человека и других вирусов в плазме крови человека с сохранением функциональной активности белков плазмы крови | |
| UA10281C2 (uk) | Спосіб отримання речовини для лікування захворювань підшлункової залози |